These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

813 related items for PubMed ID: 8807338

  • 1. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
    Kambouris M, Jackson CE, Feldman GL.
    Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338
    [Abstract] [Full Text] [Related]

  • 2. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P.
    Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
    [Abstract] [Full Text] [Related]

  • 3. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
    Sansó G, Domené HM, Iorcansky S, Barontini M.
    Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
    [Abstract] [Full Text] [Related]

  • 4. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
    Komminoth P, Kunz EK, Matias-Guiu X, Hiort O, Christiansen G, Colomer A, Roth J, Heitz PU.
    Cancer; 1995 Aug 01; 76(3):479-89. PubMed ID: 8625130
    [Abstract] [Full Text] [Related]

  • 5. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
    Sanso GE, Domene HM, Garcia R, Pusiol E, de M, Roque M, Ring A, Perinetti H, Elsner B, Iorcansky S, Barontini M.
    Cancer; 2002 Jan 15; 94(2):323-30. PubMed ID: 11900218
    [Abstract] [Full Text] [Related]

  • 6. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A.
    Landsvater RM, Jansen RP, Hofstra RM, Buys CH, Lips CJ, Ploos van Amstel HK.
    Hum Genet; 1996 Jan 15; 97(1):11-4. PubMed ID: 8557249
    [Abstract] [Full Text] [Related]

  • 7. RET oncogene mutations in medullary thyroid carcinoma in Mexican families.
    González B, Salcedo M, Medrano ME, Mantilla A, Quiñónez G, Benítez-Bribiesca L, Rodríguez-Cuevas S, Cabrera L, de León B, Altamirano N, Tapia J, Dawson B.
    Arch Med Res; 2003 Jan 15; 34(1):41-9. PubMed ID: 12604374
    [Abstract] [Full Text] [Related]

  • 8. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
    Chiefari E, Russo D, Giuffrida D, Zampa GA, Meringolo D, Arturi F, Chiodini I, Bianchi D, Attard M, Trischitta V, Bruno R, Giannasio P, Pontecorvi A, Filetti S.
    J Endocrinol Invest; 1998 Jun 15; 21(6):358-64. PubMed ID: 9699127
    [Abstract] [Full Text] [Related]

  • 9. Detection of RET mutations in multiple endocrine neoplasia type 2a and familial medullary thyroid carcinoma by denaturing gradient gel electrophoresis.
    Peacock ML, Borst MJ, Sweet JD, Decker RA.
    Hum Mutat; 1996 Jun 15; 7(2):100-4. PubMed ID: 8829625
    [Abstract] [Full Text] [Related]

  • 10. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
    Marsh DJ, Mulligan LM, Eng C.
    Horm Res; 1997 Jun 15; 47(4-6):168-78. PubMed ID: 9167949
    [Abstract] [Full Text] [Related]

  • 11. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s.
    Zedenius J, Wallin G, Hamberger B, Nordenskjöld M, Weber G, Larsson C.
    Hum Mol Genet; 1994 Aug 15; 3(8):1259-62. PubMed ID: 7987299
    [Abstract] [Full Text] [Related]

  • 12. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
    Frilling A, Dralle H, Eng C, Raue F, Broelsch CE.
    Surgery; 1995 Dec 15; 118(6):1099-103; discussion 1103-4. PubMed ID: 7491529
    [Abstract] [Full Text] [Related]

  • 13. The RET proto-oncogene and cancer.
    Donis-Keller H.
    J Intern Med; 1995 Oct 15; 238(4):319-25. PubMed ID: 7595167
    [Abstract] [Full Text] [Related]

  • 14. The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families.
    Marsh DJ, McDowall D, Hyland VJ, Andrew SD, Schnitzler M, Gaskin EL, Nevell DF, Diamond T, Delbridge L, Clifton-Bligh P, Robinson BG.
    Clin Endocrinol (Oxf); 1996 Feb 15; 44(2):213-20. PubMed ID: 8849577
    [Abstract] [Full Text] [Related]

  • 15. [Molecular diagnosis of multiple type 2 endocrine neoplasia].
    Amosenko FA, Pushkash K, Frilling A, Kozlova VN, Liubchenko LN, Kazubskaia TP, Brelysh KE, Gar'kavtseva RF, Kalinin VN.
    Vestn Ross Akad Med Nauk; 2001 Feb 15; (2):34-7. PubMed ID: 11338505
    [Abstract] [Full Text] [Related]

  • 16. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".
    Fink M, Weinhüsel A, Niederle B, Haas OA.
    Int J Cancer; 1996 Aug 22; 69(4):312-6. PubMed ID: 8797874
    [Abstract] [Full Text] [Related]

  • 17. [Detection of RET-proto-oncogene mutations in the diagnosis of Type 2 endocrine neoplasia (MEN 2)].
    Komminoth P, Muletta-Feurer S, Soltermann A, Gemsenjäger E, Bürgi H, Staub JJ, Schönle E, Fried M, Vetter W, Spinas GA, Heitz PU.
    Schweiz Med Wochenschr; 1996 Aug 06; 126(31-32):1329-38. PubMed ID: 8765374
    [Abstract] [Full Text] [Related]

  • 18. "Cold" single-strand conformational variants for mutation analysis of the RET protooncogene.
    Musholt PB, Musholt TJ, Goodfellow PJ, Zehnbauer BA, Wells SA, Moley JF.
    Surgery; 1997 Aug 06; 122(2):363-70; discussion 370-1. PubMed ID: 9288142
    [Abstract] [Full Text] [Related]

  • 19. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
    Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HP, Ponder MA, Ponder BA.
    Clin Endocrinol (Oxf); 1995 Jul 06; 43(1):123-7. PubMed ID: 7641404
    [Abstract] [Full Text] [Related]

  • 20. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A.
    Vieira AE, Mello MP, Elias LL, Lau IF, Maciel LM, Moreira AC, Castro M.
    Horm Metab Res; 2002 Apr 06; 34(4):202-6. PubMed ID: 11987030
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.